INO | Inovio Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.46 - 5.76
52 Week Range	3.84 - 14.75
Beta	0.72
Implied Volatility	94.79%
IV Rank	30.22%
Day's Volume	217,278
Average Volume	294,400
Shares Outstanding	25,964,300
Market Cap	143,322,936
Sector	Healthcare
Industry	Biotechnology
IPO Date	1998-12-08

Valuation
Profitability
Growth
Health
P/E Ratio	-1.09
Forward P/E Ratio	-2.74
EPS	-5.07
1YR Price Target	6.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	127
Country	USA
Website	INO

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

INO's peers: ATOS, NVAX, VXRT, ENVB, CWBR, OCEA, HEPA, ELEV, AVRO, TNXP

*Chart delayed

Analyzing fundamentals for INO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see INO Fundamentals page.

Watching at INO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on INO Technicals page.